Trials / Completed
CompletedNCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Conditions
- Lymphoma, Non-Hodgkin
- Lymphomas: Non-Hodgkin
- Lymphomas: Non-Hodgkin Cutaneous Lymphoma
- Lymphomas: Non-Hodgkin Diffuse Large B-Cell
- Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
- Lymphomas: Non-Hodgkin Mantle Cell
- Lymphomas: Non-Hodgkin Marginal Zone
- Lymphomas: Non-Hodgkin Peripheral T-Cell
- Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | |
| DRUG | Epratuzumab |
Timeline
- Start date
- 2000-11-01
- Primary completion
- 2007-06-01
- Completion
- 2009-09-01
- First posted
- 2006-11-10
- Last updated
- 2011-06-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00398372. Inclusion in this directory is not an endorsement.